The 7th China International Import Expo (CIIE) is currently being held. The reporter saw at the scene that Novartis' innovative drug combination for the treatment of IgA nephropathy (IgAN), including atorvastatin and fexostat (Ipropan hydrochloride capsules), made its first joint appearance. The reporter further learned from Novartis that Novartis plans to launch a "combination punch" in the field of kidney disease. Atractylodes, Ipropan Hydrochloride Capsules, and another investigational product Zigakibart will be important components of Novartis' product pipeline in the field of kidney disease, covering six major indications and rewriting the diagnosis and treatment status of IgA nephropathy and other kidney diseases in China, "the company said.
Further information shows that atorvastatin is the first non immune, highly selective IgAN precision therapy drug submitted for market in China. Ipropan Hydrochloride Capsules received accelerated approval from the US Food and Drug Administration in August this year to reduce proteinuria in adult IgA nephropathy patients at risk of rapid progression. It is currently the world's first complement bypass pathway inhibitor approved for this indication; At present, the indication of using Ipropan Hydrochloride Capsules for the treatment of paroxysmal nocturnal hemoglobin (PNH) has been approved in China, and the application for expanding indications in the field of kidney disease has also been accepted by the China National Medical Products Administration.
Li Yao, President and Managing Director of Novartis China, stated that the new kidney product portfolio showcased at the CIIE is expected to provide more accurate and safe solutions for the treatment of kidney diseases in China. "We will actively promote the simultaneous launch of these innovative drugs domestically and globally, and use 'Chinese speed' to benefit more kidney disease patients